# Effect of Hepatitis C Clearance on Insulin Resistance

> **NCT04457050** · PHASE4 · COMPLETED · sponsor: **Alexandria University** · enrollment: 160 (actual)

## Conditions studied

- Insulin Resistance
- Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir 400 milligram
- **DRUG:** Daclatasvir 60 milligram
- **DRUG:** Ribavirin 400 milligram
- **DRUG:** Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab

## Key facts

- **NCT ID:** NCT04457050
- **Lead sponsor:** Alexandria University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-30
- **Primary completion:** 2019-11-01
- **Final completion:** 2019-12-30
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04457050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04457050, "Effect of Hepatitis C Clearance on Insulin Resistance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04457050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*